Molteni Farmaceutici Plans For EU Entry Of Titan’s Six-Month Buprenorphine Implant
Molteni Farmaceutici/Titan’s Sixmo, the first six-month buprenorphine implant just approved for EU marketing, could be a valued option for a sizeable number of patients.
You may also be interested in...
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
This is a monthly update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.